Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Y-mAbs Therapeutics Q3 EPS $(0.18) Beats $(0.19) Estimate, Sales $19.95M Miss $20.93M Estimate

Author: Benzinga Newsdesk | November 13, 2023 06:34pm
Y-mAbs Therapeutics (NASDAQ:YMAB) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.19) by 5.26 percent. This is a 71.43 percent increase over losses of $(0.63) per share from the same period last year. The company reported quarterly sales of $19.95 million which missed the analyst consensus estimate of $20.93 million by 4.66 percent. This is a 59.16 percent increase over sales of $12.54 million the same period last year.

Posted In: YMAB


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist